Lab21 Conducting Tropism Testing for HIV Drug Selzentry in UK | GenomeWeb

Lab21 announced last week that it will be the first commercial laboratory in the UK to provide the companion diagnostic test for Selzentry, Pfizer's CCR5-tropism drug for the treatment of HIV.

The Cambridge, UK-based company said that it will offer the service from its UK operations "with immediate effect and will be able to receive samples from all parts of the world." Eventually, Lab21 also plans to offer the test as part of its comprehensive HIV service at its US facility in Greenville, SC.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.